-
公开(公告)号：US09969812B2
公开(公告)日：2018-05-15
申请号：US15382821
申请日：2016-12-19
Applicant: Eisai R&D Management Co., Ltd.
Inventor： Yoshimasa Sakamoto , Yusuke Adachi , Junji Matsui , Yu Kato , Yoichi Ozawa , Takanori Abe , Ken Ito , Yuya Nakazawa , Sho Tachino , Katsuhisa Suzuki , Kishan Agarwala , Kana Hoshino , Masahiko Katayama
IPC: A61K39/395 , C07K16/28 , C07K16/30 , C07K14/705 , C07K16/32 , A61K31/337 , A61K31/47 , A61K33/24 , C12N9/14 , C07K14/71 , A61K39/00
CPC classification number: C07K16/32 , A61K31/337 , A61K31/47 , A61K33/24 , A61K39/395 , A61K39/3955 , A61K39/39558 , A61K2039/505 , C07K14/705 , C07K14/71 , C07K16/28 , C07K16/2863 , C07K16/3023 , C07K16/303 , C07K2317/20 , C07K2317/24 , C07K2317/34 , C07K2317/52 , C07K2317/56 , C07K2317/565 , C07K2317/76 , C07K2317/92 , C07K2319/21 , C07K2319/42 , C12N9/14 , C12Y301/03001 , A61K2300/00
Abstract: The present invention provides an anti-human Notch4 antibody or a Notch4 binding fragment thereof that may have neutralizing activity against human Notch4, as well as a pharmaceutical composition comprising the same as the active ingredient. The present inventors obtained a mouse anti-human Notch4 antibody that has high neutralizing activity and binding affinity towards human Notch4 and determined the complementarity determining region (CDR) sequence of the mouse anti-human Notch4 antibody. This enabled the production of a humanized antibody comprising the variable region of heavy and light chains as well as the CDR sequence of the mouse anti-human Notch4 antibody.
-
公开(公告)号：US20160046707A1
公开(公告)日：2016-02-18
申请号：US14816989
申请日：2015-08-03
Applicant: Eisai R&D Management Co., Ltd.
Inventor： Toshio Imai , James Bradford Kline , Tetsu Kawano , Luigi Grasso , Yoshimasa Sakamoto , Jared Spidel , Miyuki Nishimura , Kenzo Muramoto , Tatsuo Horizoe
CPC classification number: C07K16/24 , A61K2039/505 , C07K2317/24 , C07K2317/33 , C07K2317/34 , C07K2317/76 , C07K2317/92 , G01N33/6863 , G01N2333/521
Abstract: The present invention relates to novel humanized, chimeric and murine antibodies that have binding specificity for the human CC chemokine ligand 20 (CCL20). The present invention further relates to heavy chains and light chains of said antibodies. The invention also relates to isolated nucleic acids, recombinant vectors and host cells that comprise a sequence which encodes a heavy chain and/or a light chain of said antibodies, and to a method of preparing said antibodies. The anti-CCL20 antibodies of the invention can be used in therapeutic applications to treat, for example, inflammatory and autoimmune disorders and cancer.
Abstract translation: 本发明涉及对人CC趋化因子配体20（CCL20）具有结合特异性的新型人源化，嵌合和鼠抗体。 本发明还涉及所述抗体的重链和轻链。 本发明还涉及分离的核酸，重组载体和宿主细胞，其包含编码所述抗体的重链和/或轻链的序列，以及制备所述抗体的方法。 本发明的抗CCL20抗体可用于治疗例如炎性和自身免疫性疾病和癌症的治疗应用。
-
公开(公告)号：US20190002588A1
公开(公告)日：2019-01-03
申请号：US16063515
申请日：2017-01-11
Inventor： Toshinori Nakayama , Motoko Kimura , Koji Hayashizaki , Toshifumi Hirayama , Jungo Kakuta , Yoshimasa Sakamoto , Ryu Gejima , Daisuke Tokita , Kenzo Muramoto , Toshio Imai
Abstract: The present invention provides an anti-Myl9 antibody or a Myl9 binding fragment thereof that binds to Myl9 and may inhibit the interaction between Myl9 and CD69 in humans, as well as a pharmaceutical composition comprising the same. A mouse anti-human/mouse Myl9 monoclonal antibody having binding affinity against Myl9 was obtained, and the sequence for the complementarity determining region (CDR) of said mouse anti-human/mouse Myl9 monoclonal antibody was identified. Accordingly, a humanized antibody comprising the CDR sequence of said mouse anti-human/mouse Myl9 monoclonal antibody in the variable region of heavy and light chains was produced.
-
公开(公告)号：US09527921B2
公开(公告)日：2016-12-27
申请号：US15098869
申请日：2016-04-14
Applicant: Eisai R&D Management Co., Ltd.
Inventor： Yoshimasa Sakamoto , Yusuke Adachi , Junji Matsui , Yu Kato , Yoichi Ozawa , Takanori Abe , Ken Ito , Yuya Nakazawa , Sho Tachino , Katsuhisa Suzuki , Kishan Agarwala , Kana Hoshino , Masahiko Katayama
IPC: A61K39/395 , C07K16/32 , A61K33/24 , A61K31/47 , A61K31/337 , C07K16/28 , C07K16/30 , C07K14/705 , C07K14/71 , A61K39/00
CPC classification number: C07K16/32 , A61K31/337 , A61K31/47 , A61K33/24 , A61K39/395 , A61K39/3955 , A61K39/39558 , A61K2039/505 , C07K14/705 , C07K14/71 , C07K16/28 , C07K16/2863 , C07K16/3023 , C07K16/303 , C07K2317/20 , C07K2317/24 , C07K2317/34 , C07K2317/52 , C07K2317/56 , C07K2317/565 , C07K2317/76 , C07K2317/92 , C07K2319/21 , C07K2319/42 , C12N9/14 , C12Y301/03001 , A61K2300/00
Abstract: The present invention provides an anti-human Notch4 antibody or a Notch4 binding fragment thereof that may have neutralizing activity against human Notch4, as well as a pharmaceutical composition comprising the same as the active ingredient. The present inventors obtained a mouse anti-human Notch4 antibody that has high neutralizing activity and binding affinity towards human Notch4 and determined the complementarity determining region (CDR) sequence of the mouse anti-human Notch4 antibody. This enabled the production of a humanized antibody comprising the variable region of heavy and light chains as well as the CDR sequence of the mouse anti-human Notch4 antibody.
Abstract translation: 本发明提供了可能对人Notch4具有中和活性的抗人Notch4抗体或Notch4结合片段，以及包含与活性成分相同的药物组合物。 本发明人获得了对人Notch4具有高中和活性和结合亲和力的小鼠抗人Notch4抗体，并确定了小鼠抗人Notch4抗体的互补决定区（CDR）序列。 这使得能够生产包含重链和轻链的可变区以及小鼠抗人Notch4抗体的CDR序列的人源化抗体。
-
5.发明申请Lrp4/CORIN DOPAMINE-PRODUCING NEURON PRECURSOR CELL MARKER 有权Lrp4 / CORIN DOPAMINE-PRODUCING NEURON PRECURSOR CELL MARKER公开(公告)号：US20150299654A1
公开(公告)日：2015-10-22
申请号：US14703000
申请日：2015-05-04
Applicant: Eisai R&D Management Co., Ltd.
Inventor： Yoshimasa Sakamoto , Yuichi Ono , Toshio Imai , Yasuko Nakagawa
IPC: C12N5/0797 , C12Q1/68 , G01N33/50 , G01N33/68
CPC classification number: C12N5/0623 , A61K35/30 , C07K16/286 , C12Q1/6881 , C12Q1/6883 , C12Q2600/158 , G01N33/5023 , G01N33/56966 , G01N33/6896 , G01N2500/00 , G01N2800/2835
Abstract: The present invention relates to polynucleotide probes and antibodies for detecting Lrp4/Corin dopaminergic neuron progenitor cell markers, which enable the efficient separation of dopaminergic neuron progenitor cells; and methods for selecting the progenitor cells by the use thereof.
Abstract translation: 本发明涉及用于检测Lrp4 / Corin多巴胺能神经元祖细胞标记物的多核苷酸探针和抗体，其能够有效分离多巴胺能神经元祖细胞; 以及通过其使用来选择祖细胞的方法。
-
Patent Agency Ranking
公开(公告)号：US09133273B2
公开(公告)日：2015-09-15
申请号：US13924433
申请日：2013-06-21
Applicant: Eisai R&D Management Co., Ltd.
Inventor： Toshio Imai , James Bradford Kline , Tetsu Kawano , Luigi Grasso , Yoshimasa Sakamoto , Jared Spidel , Miyuki Nishimura , Kenzo Muramoto , Tatsuo Horizoe
CPC classification number: C07K16/24 , A61K2039/505 , C07K2317/24 , C07K2317/33 , C07K2317/34 , C07K2317/76 , C07K2317/92 , G01N33/6863 , G01N2333/521
Abstract: The present invention relates to novel humanized, chimeric and murine antibodies that have binding specificity for the human CC chemokine ligand 20 (CCL20). The present invention further relates to heavy chains and light chains of said antibodies. The invention also relates to isolated nucleic acids, recombinant vectors and host cells that comprise a sequence which encodes a heavy chain and/or a light chain of said antibodies, and to a method of preparing said antibodies. The anti-CCL20 antibodies of the invention can be used in therapeutic applications to treat, for example, inflammatory and autoimmune disorders and cancer.
Abstract translation: 本发明涉及对人CC趋化因子配体20（CCL20）具有结合特异性的新型人源化，嵌合和鼠抗体。 本发明还涉及所述抗体的重链和轻链。 本发明还涉及分离的核酸，重组载体和宿主细胞，其包含编码所述抗体的重链和/或轻链的序列，以及制备所述抗体的方法。 本发明的抗CCL20抗体可用于治疗例如炎性和自身免疫性疾病和癌症的治疗应用。
-
公开(公告)号：US10513561B2
公开(公告)日：2019-12-24
申请号：US16063515
申请日：2017-01-11
Inventor： Toshinori Nakayama , Motoko Kimura , Koji Hayashizaki , Toshifumi Hirayama , Jungo Kakuta , Yoshimasa Sakamoto , Ryu Gejima , Daisuke Tokita , Kenzo Muramoto , Toshio Imai
IPC: A61K39/395 , A61P37/08 , A61P37/02 , A61P35/00 , A61P1/00 , C07K16/18 , C07K16/46 , A61P11/00 , A61P1/04 , C07K16/28 , C07K14/47 , C12N15/09
Abstract: The present invention provides an anti-Myl9 antibody or a Myl9 binding fragment thereof that binds to Myl9 and may inhibit the interaction between Myl9 and CD69 in humans, as well as a pharmaceutical composition comprising the same. A mouse anti-human/mouse Myl9 monoclonal antibody having binding affinity against Myl9 was obtained, and the sequence for the complementarity determining region (CDR) of said mouse anti-human/mouse Myl9 monoclonal antibody was identified. Accordingly, a humanized antibody comprising the CDR sequence of said mouse anti-human/mouse Myl9 monoclonal antibody in the variable region of heavy and light chains was produced.
-
公开(公告)号：US20170096493A1
公开(公告)日：2017-04-06
申请号：US15382821
申请日：2016-12-19
Applicant: Eisai R&D Management Co., Ltd.
Inventor： Yoshimasa Sakamoto , Yusuke Adachi , Junji Matsui , Yu Kato , Yoichi Ozawa , Takanori Abe , Ken Ito , Yuya Nakazawa , Sho Tachino , Katsuhisa Suzuki , Kishan Agarwala , Kana Hoshino , Masahiko Katayama
IPC: C07K16/32 , A61K31/337 , A61K31/47 , A61K39/395 , A61K33/24
CPC classification number: C07K16/32 , A61K31/337 , A61K31/47 , A61K33/24 , A61K39/395 , A61K39/3955 , A61K39/39558 , A61K2039/505 , C07K14/705 , C07K14/71 , C07K16/28 , C07K16/2863 , C07K16/3023 , C07K16/303 , C07K2317/20 , C07K2317/24 , C07K2317/34 , C07K2317/52 , C07K2317/56 , C07K2317/565 , C07K2317/76 , C07K2317/92 , C07K2319/21 , C07K2319/42 , C12N9/14 , C12Y301/03001 , A61K2300/00
Abstract: The present invention provides an anti-human Notch4 antibody or a Notch4 binding fragment thereof that may have neutralizing activity against human Notch4, as well as a pharmaceutical composition comprising the same as the active ingredient. The present inventors obtained a mouse anti-human Notch4 antibody that has high neutralizing activity and binding affinity towards human Notch4 and determined the complementarity determining region (CDR) sequence of said mouse anti-human Notch4 antibody. This enabled the production of a humanized antibody comprising the variable region of heavy and light chains as well as the CDR sequence of said mouse anti-human Notch4 antibody.
-
公开(公告)号：US09994816B2
公开(公告)日：2018-06-12
申请号：US14703000
申请日：2015-05-04
Applicant: Eisai R&D Management Co., Ltd.
Inventor： Yoshimasa Sakamoto , Yuichi Ono , Toshio Imai , Yasuko Nakagawa
IPC: G01N33/50 , C12N5/0797 , C07K16/28 , C12Q1/68 , G01N33/569 , G01N33/68 , A61K35/30
CPC classification number: C12N5/0623 , A61K35/30 , C07K16/286 , C12Q1/6881 , C12Q1/6883 , C12Q2600/158 , G01N33/5023 , G01N33/56966 , G01N33/6896 , G01N2500/00 , G01N2800/2835
Abstract: The present invention relates to polynucleotide probes and antibodies for detecting Lrp4/Corin dopaminergic neuron progenitor cell markers, which enable the efficient separation of dopaminergic neuron progenitor cells; and methods for selecting the progenitor cells by the use thereof.
-
公开(公告)号：US09809647B2
公开(公告)日：2017-11-07
申请号：US14816989
申请日：2015-08-03
Applicant: Eisai R&D Management Co., Ltd.
Inventor： Toshio Imai , James Bradford Kline , Tetsu Kawano , Luigi Grasso , Yoshimasa Sakamoto , Jared Spidel , Miyuki Nishimura , Kenzo Muramoto , Tatsuo Horizoe
CPC classification number: C07K16/24 , A61K2039/505 , C07K2317/24 , C07K2317/33 , C07K2317/34 , C07K2317/76 , C07K2317/92 , G01N33/6863 , G01N2333/521
Abstract: The present invention relates to novel humanized, chimeric and murine antibodies that have binding specificity for the human CC chemokine ligand 20 (CCL20). The present invention further relates to heavy chains and light chains of said antibodies. The invention also relates to isolated nucleic acids, recombinant vectors and host cells that comprise a sequence which encodes a heavy chain and/or a light chain of said antibodies, and to a method of preparing said antibodies. The anti-CCL20 antibodies of the invention can be used in therapeutic applications to treat, for example, inflammatory and autoimmune disorders and cancer.
-
-
-
-
-
-
-
-
-
Search Results
11
records
(took 0.029 seconds)
